Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abbas F Almulla

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Brain Sciences|May 27, 2023
Research and Diagnostic Algorithmic Rules (RADAR) and RADAR Plots for the First Episode of Major Depressive Disorder: Effects of Childhood and Recent Adverse Experiences on Suicidal Behaviors, Neurocognition and Phenome FeaturesMichael Maes, Abbas F Almulla
CNS Drugs|June 13, 2025
Peripheral Immune-Inflammatory Pathways in Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: Exploring Their Potential as Treatment TargetsAbbas F Almulla, Michael Maes
Neurotoxicity Research|January 10, 2020
The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning StudyHussein Kadhem Al-Hakeim, Abbas F Almulla, Michael Maes
CNS Spectrums|May 21, 2020
Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophreniaAbbas F Almulla, Hussein K Al-Hakeim, Michael Maes
Expert Opinion on Therapeutic Targets|December 19, 2025
Advancements in the molecular understanding of major depressive disorder uncovering novel targets with therapeutic promise: focus on recurrence of illnessMichael Maes, Abbas F Almulla, Drozdstoj Stoyanov, et al.
Nature Reviews. Neurology|July 14, 2025
Neuroimmune, metabolic and oxidative stress pathways in major depressive disorderMichael Maes, Abbas F Almulla, Zili You, et al.
Cellular & Molecular Immunology|July 12, 2026
Unifying the hallmarks of major depression through neuroimmune-metabolic-oxidative (NIMETOX) dysregulation: a mechanistic systems frameworkMichael Maes, Abbas F Almulla, Drozdstoj Stoyanov, et al.
Psychiatry Research|March 5, 2024
Adverse childhood experiences and recent negative events are associated with activated immune and growth factor pathways, the phenome of first episode major depression and suicidal behaviorsAbbas F Almulla, Ali Abbas Abo Algon, Michael Maes
Autism Research : Official Journal of the International Society for Autism Research|November 1, 2023
The tryptophan catabolite or kynurenine pathway in autism spectrum disorder; a systematic review and meta-analysisAbbas F Almulla, Yanin Thipakorn, Chavit Tunvirachaisakul, et al.
Antioxidants (Basel, Switzerland)|May 28, 2022
A Novel Pathway Phenotype of Temporal Lobe Epilepsy and Comorbid Psychiatric Disorders: Results of Precision Nomothetic MedicineMichael Maes, Décio Sabbatini Barbosa, Abbas F Almulla, et al.
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Brain Sciences|May 27, 2023
Research and Diagnostic Algorithmic Rules (RADAR) and RADAR Plots for the First Episode of Major Depressive Disorder: Effects of Childhood and Recent Adverse Experiences on Suicidal Behaviors, Neurocognition and Phenome FeaturesMichael Maes, Abbas F Almulla
CNS Drugs|June 13, 2025
Peripheral Immune-Inflammatory Pathways in Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: Exploring Their Potential as Treatment TargetsAbbas F Almulla, Michael Maes
Neurotoxicity Research|January 10, 2020
The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning StudyHussein Kadhem Al-Hakeim, Abbas F Almulla, Michael Maes
CNS Spectrums|May 21, 2020
Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophreniaAbbas F Almulla, Hussein K Al-Hakeim, Michael Maes
Expert Opinion on Therapeutic Targets|December 19, 2025
Advancements in the molecular understanding of major depressive disorder uncovering novel targets with therapeutic promise: focus on recurrence of illnessMichael Maes, Abbas F Almulla, Drozdstoj Stoyanov, et al.
Nature Reviews. Neurology|July 14, 2025
Neuroimmune, metabolic and oxidative stress pathways in major depressive disorderMichael Maes, Abbas F Almulla, Zili You, et al.
Cellular & Molecular Immunology|July 12, 2026
Unifying the hallmarks of major depression through neuroimmune-metabolic-oxidative (NIMETOX) dysregulation: a mechanistic systems frameworkMichael Maes, Abbas F Almulla, Drozdstoj Stoyanov, et al.
Psychiatry Research|March 5, 2024
Adverse childhood experiences and recent negative events are associated with activated immune and growth factor pathways, the phenome of first episode major depression and suicidal behaviorsAbbas F Almulla, Ali Abbas Abo Algon, Michael Maes
Autism Research : Official Journal of the International Society for Autism Research|November 1, 2023
The tryptophan catabolite or kynurenine pathway in autism spectrum disorder; a systematic review and meta-analysisAbbas F Almulla, Yanin Thipakorn, Chavit Tunvirachaisakul, et al.
Antioxidants (Basel, Switzerland)|May 28, 2022
A Novel Pathway Phenotype of Temporal Lobe Epilepsy and Comorbid Psychiatric Disorders: Results of Precision Nomothetic MedicineMichael Maes, Décio Sabbatini Barbosa, Abbas F Almulla, et al.
Pageof 9